ESR1 and breast carcinoma: Part of the reason that TNBCs have limited treatment options is that they are deficient in three traditional protein targets of breast cancer therapy—the estrogen receptor (ER); the progesterone receptor (PR); and the human epidermal growth factor receptor 2 (HER2) [3,4,5].